XNASKPTI
Market cap90mUSD
Jan 13, Last price
0.67USD
1D
0.36%
1Q
-16.56%
Jan 2017
-92.36%
IPO
-95.50%
Name
Karyopharm Therapeutics Inc
Chart & Performance
Profile
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 146,033 -7.03% | 157,074 -25.14% | |||||||
Cost of revenue | 275,573 | 299,276 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (129,540) | (142,202) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 323 | 369 | |||||||
Tax Rate | |||||||||
NOPAT | (129,863) | (142,571) | |||||||
Net income | (143,099) -13.43% | (165,291) 33.20% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 1,124 | 193,738 | |||||||
BB yield | -1.14% | -69.60% | |||||||
Debt | |||||||||
Debt current | 6,616 | 2,872 | |||||||
Long-term debt | 179,805 | 179,074 | |||||||
Deferred revenue | 132,718 | ||||||||
Other long-term liabilities | 133,457 | 204,723 | |||||||
Net debt | (5,022) | (96,654) | |||||||
Cash flow | |||||||||
Cash from operating activities | (92,723) | (149,554) | |||||||
CAPEX | (118) | ||||||||
Cash from investing activities | 7,940 | (104,256) | |||||||
Cash from financing activities | 1,124 | 193,738 | |||||||
FCF | (119,273) | (156,401) | |||||||
Balance | |||||||||
Cash | 191,443 | 277,967 | |||||||
Long term investments | 633 | ||||||||
Excess cash | 184,141 | 270,746 | |||||||
Stockholders' equity | (1,487,187) | (1,344,565) | |||||||
Invested Capital | 1,664,762 | 1,772,419 | |||||||
ROIC | |||||||||
ROCE | |||||||||
EV | |||||||||
Common stock shares outstanding | 114,221 | 81,871 | |||||||
Price | 0.87 -74.56% | 3.40 -47.12% | |||||||
Market cap | 98,801 -64.51% | 278,361 -42.45% | |||||||
EV | 93,779 | 181,707 | |||||||
EBITDA | (129,010) | (141,581) | |||||||
EV/EBITDA | |||||||||
Interest | 23,823 | 24,996 | |||||||
Interest/NOPBT |